Literature DB >> 8636151

A blood group-related polymorphism of CD44 abolishes a hyaluronan-binding consensus sequence without preventing hyaluronan binding.

M J Telen1, M Udani, M K Washington, M C Levesque, E Lloyd, N Rao.   

Abstract

CD44 is a widely expressed integral membrane protein that acts as a receptor for hyaluronan (HA) and is proposed to be important to cell-extracellular matrix interaction. The Indian (In) blood group antigens reside on CD44, and most individuals express the Inb antigen. Homozygosity for the Ina allele occurs as a rare event and is associated with production of alloantibody to the common Inb antigen after transfusion or pregnancy. The present study demonstrates that a single point mutation (G252 --> C) causes an Arg46 --> Pro substitution, which is responsible for the Inb/Ina polymorphism. Additional mutations were found in In(a+b-) cDNA but were not necessary to the antigenic phenotype as determined in site-directed mutagenesis studies. In studies using CD44 chimeric constructs, Arg46 has previously been shown to be crucial for maintenance of HA-binding ability to a CD44 peptide. However, the present study demonstrates that the Arg46 --> Pro substitution does not reduce HA binding to the intact CD44 protein, which contains two proposed extracellular HA-binding motifs. Down-regulation of HA binding to In(a+b-) CD44 by anti-CD44 monoclonal antibody (mAb) ligands, however, was weakened, although all mAbs tested bound In(a+b-) and In(a-b+) CD44 equally well. Competitive inhibition studies using human anti-Inb also showed that some mAbs that inhibit HA binding to CD44 may do so by interacting with a domain separate from, but affecting the structure of, the Inb epitope.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636151     DOI: 10.1074/jbc.271.12.7147

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Unique SNP in CD44 intron 1 and its role in breast cancer development.

Authors:  Juhua Zhou; Prakash S Nagarkatti; Yin Zhong; Kim Creek; Jiajia Zhang; Mitzi Nagarkatti
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

Review 2.  Forms and functions of CD44.

Authors:  G Borland; J A Ross; K Guy
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

Review 3.  CD44 in inflammation and metastasis.

Authors:  J Lesley; R Hyman; N English; J B Catterall; G A Turner
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

4.  Implications of single nucleotide polymorphisms in CD44 exon 2 for risk of breast cancer.

Authors:  Juhua Zhou; Prakash S Nagarkatti; Yin Zhong; Jiajia Zhang; Mitzi Nagarkatti
Journal:  Eur J Cancer Prev       Date:  2011-09       Impact factor: 2.497

5.  Molecular typing for the Indian blood group associated 252G>C single nucleotide polymorphism in a selected cohort of Australian blood donors.

Authors:  Genghis H Lopez; Rhiannon S Mcbean; Brett Wilson; Darryl L Irwin; Yew-Wah Liew; Catherine A Hyland; Robert L Flower
Journal:  Blood Transfus       Date:  2014-06-05       Impact factor: 3.443

6.  Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin.

Authors:  M Udani; Q Zen; M Cottman; N Leonard; S Jefferson; C Daymont; G Truskey; M J Telen
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

7.  4.1R-deficient human red blood cells have altered phosphatidylserine exposure pathways and are deficient in CD44 and CD47 glycoproteins.

Authors:  Kris P Jeremy; Zoe E Plummer; David J Head; Tracey E Madgett; Kelly L Sanders; Amanda Wallington; Jill R Storry; Florinda Gilsanz; Jean Delaunay; Neil D Avent
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

8.  BOOGIE: Predicting Blood Groups from High Throughput Sequencing Data.

Authors:  Manuel Giollo; Giovanni Minervini; Marta Scalzotto; Emanuela Leonardi; Carlo Ferrari; Silvio C E Tosatto
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

9.  Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.

Authors:  Norbert Vey; Jacques Delaunay; Giovanni Martinelli; Walter Fiedler; Emmanuel Raffoux; Thomas Prebet; Carlos Gomez-Roca; Cristina Papayannidis; Maxim Kebenko; Peter Paschka; Randolph Christen; Ernesto Guarin; Ann-Marie Bröske; Monika Baehner; Michael Brewster; Antje-Christine Walz; Francesca Michielin; Valeria Runza; Valerie Meresse; Christian Recher
Journal:  Oncotarget       Date:  2016-05-31

10.  CD44 gene polymorphisms in breast cancer risk and prognosis: a study in North Indian population.

Authors:  Sonam Tulsyan; Gaurav Agarwal; Punita Lal; Sushma Agrawal; Rama Devi Mittal; Balraj Mittal
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.